Printer Friendly

DEPRENYL USA REPORTS POSITIVE INDEPENDENT STUDY OF ITS PROPOSED TREATMENT FOR SKIN CANCERS AND OTHER DERMATOLOGICAL DISORDERS

 PARSIPPANY, N.J., Jan. 18 /PRNewswire/ -- Deprenyl USA, Inc. (NASDAQ: DUSA) today reported that the first published independent study of its proposed treatment for skin cancers and other dermatological disorders appeared in the January 1993 issue of the Journal of the American Academy of Dermatology.
 The study, conducted by a group of doctors led by Peter Wolf, M.D., of the Department of Dermatology at the University of Graz, Austria, concluded that topical photodynamic therapy with ALA "is effective for superficial epithelial skin tumors.
 "We observed a complete response after a single treatment for all nine solar keratoses, 5 of 6 early invasive squamous cellcar cinomas, and 36 of 37 superficial basal cell carcinomas," the scientists reported. "The treatment was well tolerated by all patients without local anesthetics."
 Deprenyl USA is developing ALA photodynamic therapy for these and other indications under exclusive license from Queen's University in Kingston, Ontario, Canada. Clinical trials in the United States are expected to begin shortly. Photodynamic therapy (PDT) uses a photosensitizing compound combined with the application of visible light to induce a therapeutic effect.
 The researchers added that, "unfortunately, the photosensitizers in common use, HPD or Photofrin II, persist in the skin for several weeks to several months after injection, which results in generalized photosensitivity. In contrast, the skin photosensitivity caused by ALA is restricted to the tumor and vanishes within 24 hours after treatment."
 Deprenyl USA is a development stage company established to develop prescription pharmaceutical products for worldwide markets initially in the United States and Canada, primarily in the field of photodynamic therapy.
 Common stock and warrants are traded on NASDAQ under the symbols DUSA and DUSAW. They also trade on the Toronto Stock Exchange under the symbols DPU and DPU.WT.
 -0- 1/18/93
 /CONTACT: D. Geoffrey Shulman, M.D., president & CEO, 416-537-1070 or 416-537-4372, or (fax) 416-537-0258; Joseph P. Castelli, vice president, 201-299-9070, or (fax) 201-335-0372, both of Deprenyl USA, Inc.; or Jim Tolan, senior vice president, or Nicholas Biro, partner of O'Connor Biro & Associates, 708-498-2284, or (fax) 708-498-3144, for Deprenyl USA, Inc./
 (DUSA)


CO: Deprenyl USA, Inc. ST: New Jersey IN: MTC SU:

TS -- NY032 -- 5842 01/18/93 11:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 18, 1993
Words:364
Previous Article:DANIELSON HOLDING TO ACQUIRE HOMEFED TRUST COMPANY
Next Article:ROYAL AIR MAROC CHOOSES BOEING 737s
Topics:


Related Articles
NEW HOPE FOR VICTIMS OF SKIN AND INTERNAL CANCERS
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE
DEPRENYL USA, INC. SIGNS AGREEMENT ON ADDITIONAL PHOTODYNAMIC CANCER FIGHTING COMPOUNDS
DEPRENYL USA, INC. REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPT. 30, 1992; EXPECTS TO FILE ITS FIRST INVESTIGATIONAL NEW DRUG
DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
DEPRENYL USA INC. GRANTS MEDICIS RIGHT TO FIRST REFUSAL TO MARKET IN THE U.S.; POTENTIAL BREAKTHROUGH DRUG FOR SKIN CANCER, PSORIASIS, AND WARTS
DEPRENYL USA'S EXPERIMENTAL DRUG HAS POTENTIAL AS 'TREATMENT OF CHOICE' FOR SKIN CANCERS, SAYS PRESIDENT; NAME CHANGED TO DUSA PHARMACEUTICALS
ARCTURUS REPORTS PRECLINICAL RESULTS OF TOPICAL METHOTREXATE FORMULATION FOR SKIN DISORDERS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters